Clinical Trials Browser

Advanced Cancers

NCT07260708 2026-04-21

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Phase 1 Recruiting

42 enrolled

Advanced Cancers

NCT06649656 2024-10-21

A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

Phase 1 Not yet recruiting

100 enrolled

Advanced Cancers

NCT06413953 2024-07-03

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Phase 1 Recruiting

140 enrolled

Advanced Cancers

NCT03375983 2024-02-20

Plasmodium Immunotherapy for Advanced Cancers

Phase 1/2 Recruiting

20 enrolled

Advanced Cancers

NCT05333276 2023-07-27

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Phase 1 Unknown

7 enrolled

Advanced Cancers

NCT01430572 2023-06-06

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase 1 Completed

62 enrolled

Other solid neoplasm

Advanced Cancers

NCT02042989 2022-07-11

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Phase 1 Completed

68 enrolled

Advanced Cancers

NCT05380882 2022-05-19

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

Phase 1 Unknown

60 enrolled

Advanced Cancers

NCT02561234 2021-11-05

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Phase 1/2 Completed

98 enrolled

Advanced Cancers

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase 1 Terminated

178 enrolled

Advanced Cancers

NCT01021072 2021-02-16

A First in Man Study of MABp1 in Patients With Advanced Cancers

Phase 1 Completed

52 enrolled

Advanced Cancers

NCT02597478 2021-02-09

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Phase 2/3 Completed

50 enrolled 14 charts

Advanced Cancers

NCT02521194 2020-01-13

Occupational Therapy in Palliative Care

Phase NA Terminated

86 enrolled

Advanced Cancers

NCT02498899 2019-03-19

Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion

Phase NA Completed

148 enrolled

Advanced Cancers

NCT01213238 2019-03-15

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Phase 1 Completed

116 enrolled

Advanced Cancers

NCT00836927 2019-02-18

MK-8669-038

Phase 2 Terminated

7 enrolled 13 charts

Advanced Cancers

NCT00877773 2016-08-25

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Phase 1/2 Terminated

44 enrolled 5 charts

Advanced Cancers

NCT01532011 2016-07-04

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Phase 1 Completed

72 enrolled

Other solid neoplasm

Advanced Cancers

NCT01454804 2016-04-13

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Phase 1 Completed

43 enrolled

Advanced Cancers

NCT00941499 2015-11-18

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Phase 1 Completed

140 enrolled

Advanced Cancers

NCT00895362 2015-07-13

Erlotinib in Combination With Cetuximab

Phase 1 Completed

65 enrolled

Advanced Cancers

NCT01201694 2015-01-08

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

Phase 1 Completed

28 enrolled

Advanced Cancers

NCT02193672 2014-07-18

A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

Phase 1 Withdrawn

Advanced Cancers

NCT01200004 2013-08-02

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Phase 1 Terminated

1 enrolled

Advanced Cancers

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Phase 1 Withdrawn

Advanced Cancers

NCT00473720 2013-01-23

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Phase 1 Completed

15 enrolled

Advanced Cancers

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

Phase 1 Withdrawn

Advanced Cancers

NCT00496444 2012-08-01

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Phase 1 Completed

69 enrolled

Advanced Cancers

NCT00903708 2012-07-30

LY2275796 in Advanced Cancer

Phase 1 Completed

24 enrolled

Advanced Cancers

Clinical Trials

The Effects of Ginseng on Cancer-Related Fatigue

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Plasmodium Immunotherapy for Advanced Cancers

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

A First in Man Study of MABp1 in Patients With Advanced Cancers

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Occupational Therapy in Palliative Care

Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

MK-8669-038

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Erlotinib in Combination With Cetuximab

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Study of Curcumin, Vorinostat, and Sorafenib

Azacytidine and Valproic Acid in Patients With Advanced Cancers

LY2275796 in Advanced Cancer